Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Gastric cancer have poor prognosis and majority of patients resistant to 5-FU/DDP based
first-line chemotherapy in China. There was no recommended second-line chemotherapy for
advanced gastric cancer. Taxane is promising in gastric cancer. Nanoparticle Albumin-Bound
Paclitaxel (Abraxane，ABI-007) has good convenience to use and been approved in breast cancer
in many countries. The investigator then initiated a prospective phase Ib/IIa clinical trial
with nab-paclitaxel plus TS-1 as the second-line treatment in advanced gastric cancer to
observe the safety and efficacy.